AlphAIAlphAI — Financial news for AI agents
medicaldaily.comOCT 22 min read$TEVA

Teva's Degevma Wins FDA Approval, Joining a Crowded Field of Xgeva Biosimilars for Cancer That Reaches Bone

Teva Pharmaceuticals' Degevma, a biosimilar to Amgen's Xgeva, received FDA approval for preventing bone complications in cancer patients. Teva aims to launch Degevma and its companion product, Ponlimsi, in the U.S. soon, with pricing and insurance coverage details pending. The approval adds to the growing list of Xgeva biosimilars, potentially increasing treatment options and lowering costs for patients.

Original reporting
medicaldaily.com
Published Oct 2, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 3:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva's Degevma Wins FDA Approval, Joining a Crowded Field of Xgeva Biosimilars for Cancer That Reaches Bone — source image
Source · medicaldaily.com
Decision brief

The 30-second read

$TEVABullishLow
01

Why it matters

The approval could generate incremental revenue for Teva and increase pricing competition for bone‑targeting cancer therapies.

02

Market read

First‑time FDA approval for Teva's Degevma may boost Teva's stock modestly and intensify competition in the denosumab market.

03

What to watch

Reimbursement decisions and interchangeability status could delay commercial impact.

Relevance 7/10Novelty 8/10Timing: today

Background

Teva announced FDA approval of Degevma, a denosumab biosimilar to Amgen's Xgeva, expanding its oncology biosimilar pipeline.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approved Teva's biosimilar Degevma (denosumab-adet) for cancer-related bone complications.

Expected impact

modest upside as market prices in the new product launch and potential market share gain from Xgeva.

Evidence & confidence

First FDA approval for this biosimilar; no price disclosed yet, but competition in the denosumab market may boost Teva's sales.

Market effects

Sector

Adds competitive pressure in the oncology biosimilar space, potentially affecting Amgen's Xgeva sales.

Regional

U.S. market for bone‑targeting cancer therapies sees increased supply, may modestly affect pricing dynamics.

Global

Highlights growing biosimilar activity worldwide, reinforcing trend of cost‑reduction in biologics.

Counterpoint

What could challenge this read

Without disclosed pricing, the launch may not materially move Teva's stock; competition could compress margins.

Key entities

  • Company
    Teva Pharmaceuticals

    US‑listed pharmaceutical company (ticker TEVA) receiving FDA approval for a new biosimilar.

  • Company
    Amgen

    Manufacturer of Xgeva, the reference product for the new biosimilar.

Read at source← All news

Related articles

OCT 1
$TEVAHigh

TD Cowen initiates Teva Pharma stock with buy rating on pipeline

TD Cowen initiated coverage on Teva Pharmaceutical (TEVA) with a buy rating and $55 price target, citing its pipeline and growth prospects. TEVA is near its 52-week high and has returned 98% over the past year. The FDA accepted Teva's NDA for ecopipam, and Moody's upgraded the company to investment grade. Other analysts also see growth potential in Teva's products.

investing.com2 min
OCT 1
$TEVAMed

Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar

Teva Pharmaceutical (TEVA) and Samsung Bioepis agreed to develop and commercialize up to six biosimilar candidates, including SB41 and SB44. Teva will handle sales in key markets, while Samsung Bioepis leads development. TEVA is trading at $39.60, deemed 137.8% overvalued by GF Value™, with a GF Score™ of 60. Insiders sold $14.6M in shares over the past year.

gurufocus.com2 min
SEP 30
$TEVALow

Teva Pharmaceutical Names Serge Rogasik CEO of TAPI Division, Ti

Teva Pharmaceutical (TEVA) appointed Serge Rogasik as CEO of its Technology & API Services division. The company's stock is trading at $39.60, 137.8% above its GF Value™ of $16.65, indicating significant overvaluation. TEVA has a GF Score™ of 60, with strengths in profitability and momentum but weaknesses in financial strength, growth, and valuation. Insiders have sold $14.6 million in shares over the past year with no insider buying.

gurufocus.com2 min
SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAHighAI 9/10

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

biopharminternational.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min